Evidence map›Paper›PMID 39623490›Full record

ArticleStem cell research & therapy2024

Knockout of B2M in combination with PD-L1 overexpression protects MSC-derived new islet β cells from graft rejection in the treatment of canine diabetes mellitus.

Pengxiu Dai, Yi Wu, Qingjie Du, Juanjuan Du, Keyi Wang, Ruiqi Chen, Xiancheng Feng, Chen Chen, Xinke Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pengxiu DaiThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China.
Yi WuThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China.
Qingjie DuThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China.
Juanjuan DuThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China.
Keyi WangThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China.
Ruiqi ChenThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China.
Xiancheng FengThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China.
Chen ChenMOA Key Laboratory of Animal Virology, Center for Veterinary Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
Xinke ZhangThe College of Veterinary Medicine, Northwest Agriculture and Forestry University, Shaanxi, 712100, Yangling, China. zxk19830521@163.com.

Funding

2023 Animal Epidemic Prevention project K3031223086Shaanxi Province postdoctoral research project second-class funding 2023BSHEDZZ144
6 · The paper itself

Abstract

backgroundThe immunogenicity of allogeneic mesenchymal stem cells (MSCs) is significantly enhanced after transplantation or differentiation, and these cells can be recognized and cleared by recipient immune cells. Graft rejection has become a major obstacle to improving the therapeutic effect of allogeneic MSCs or, after their differentiation, transplantation in the treatment of diabetes and other diseases. Solving this problem is helpful for prolonging the time that cells play a role in the recipient body and for significantly improving the clinical therapeutic effect.

methodsIn this study, canine adipose-derived mesenchymal stem cells (ADSCs) were used as seed cells, and gene editing technology was used to knock out the B2M gene in these cells and cooperate with the overexpression of the PD-L1 gene. Gene-edited ADSCs (GeADSCs), whose biological characteristics and safety are not different from those of normal canine ADSCs, have been obtained.

resultsThe immunogenicity of GeADSCs is reduced, the immune escape ability of GeADSCs is enhanced, and GeADSCs can remain in the body for a longer time. Using the optimized induction program, the efficiency of the differentiation of GeADSCs into new islet β-cells was increased, and the maturity of the new islet β-cells was increased. The immunogenicity of new islet β-cells decreased, and their immune escape ability was enhanced after the cells were transplanted into diabetic dogs (the graft site was prevascularized by the implantation of a scaffold to form a vascularized pouch). The number of infiltrating immune cells and the content of immune factors were decreased at the graft site.

conclusionsNew islet β-cell transplantation, which has low immunogenicity, can reverse diabetes in dogs, and the therapeutic effect of cell transplantation is significantly enhanced. This study provides a new method for prolonging the survival and functional time of cells in transplant recipients and significantly improving the clinical therapeutic effect.

Indexed as

B7-H1 AntigenGraft RejectionInsulin-Secreting CellsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsCell DifferentiationDiabetes MellitusDiabetes Mellitus, ExperimentalDogsB7-H1 AntigenAntigraft rejectionGene-edited ADSCsImmunogenicityNew islet β cellsTherapeutic effect

Identifiers

PMID39623490
PMCPMC11613808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.